| Title |
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy
|
|---|---|
| Published in |
Investigational New Drugs, September 2017
|
| DOI | 10.1007/s10637-017-0516-2 |
| Pubmed ID | |
| Authors |
Francesco Pasqualetti, Alessandra Gonnelli, Martina Cantarella, Durim Delishaj, Alessandro Molinari, Valerio Ortenzi, Francesco Carbone, Sabrina Montrone, Stefano Ursino, Sara Franceschi, Riccardo Morganti, Paola Orlandi, Teresa Di Desidero, Chiara Maria Mazzanti, Katia Zavaglia, Antonio Giuseppe Naccarato, Guido Bocci, Fabiola Paiar |
| Abstract |
Glioblastoma (GBM) is the most frequent malignant primary brain tumor in adults and, despite recent advances, the prognosis for this cancer remains dismal. The aims of this study were to test the influence of XRCC1 rs25487, XRCC3 rs861539, XRCC3 rs1799794, RAD51 rs1801320 and GSTP-1 rs1695 single nucleotide polymorphisms on progression free survival (PFS) and overall survival (OS) in GBM patients treated with radiotherapy (RT) and temozolomide (TMZ). Fifty GBM patients treated with upfront radio-chemotherapy (RT 60 Gy/30 sessions; TMZ 75 mg/m(2) during RT and 200 mg/m(2) days 1 → 5 every 28 days) were enrolled. Survival curves were calculated using the Kaplan-Meier method, and the log-rank test was used to evaluate differences between curves. A trend to a statistically significant association with PFS in univariate and multivariate COX regression analysis was found with GSTP-1 rs1695 polymorphism (p = 0.087 and p = 0.097 on univariate and multivariate analyses, respectively). Conversely, the same GSTP-1 rs1695 SNP revealed a statistically significant association with OS (p = 0.007 and p = 0.042 on univariate and multivariate analysis, respectively). Our pharmacogenetic prospective study suggests that GSTP-1 rs1695 genotypes can be associated with different OS in GBM patients treated with RT and TMZ. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 18 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 22% |
| Lecturer > Senior Lecturer | 2 | 11% |
| Other | 2 | 11% |
| Student > Ph. D. Student | 2 | 11% |
| Researcher | 2 | 11% |
| Other | 1 | 6% |
| Unknown | 5 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 39% |
| Biochemistry, Genetics and Molecular Biology | 3 | 17% |
| Nursing and Health Professions | 2 | 11% |
| Neuroscience | 1 | 6% |
| Unknown | 5 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2019.
All research outputs
#18,573,839
of 23,005,189 outputs
Outputs from Investigational New Drugs
#880
of 1,174 outputs
Outputs of similar age
#246,403
of 321,749 outputs
Outputs of similar age from Investigational New Drugs
#10
of 17 outputs
Altmetric has tracked 23,005,189 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,174 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,749 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.